Corrigendum to "Outcomes of Programmed Cell Death Protein 1 (PD-1) and Programmed Death-Ligand 1 (PD-L1) Inhibitor Therapy in HIV Patients with Advanced Cancer"

J Oncol. 2019 Aug 21:2019:7921582. doi: 10.1155/2019/7921582. eCollection 2019.

Authors

Shahla Bari¹, Jameel Muzaffar², Austin Chan³, Sanjay R Jain³, Ahmad M Haider⁴, Marjorie Adams Curry⁵, Christopher J Hostler⁶

Affiliations

¹ Internal Medicine, Morehouse School of Medicine, Atlanta, GA, USA.
² Department of Head and Neck-Endocrine Oncology, Moffitt Cancer Center, Tampa, FL, USA.
³ Morehouse School of Medicine, Atlanta, GA, USA.
⁴ AGCO Corporation, Atlanta, GA, USA.
⁵ Grady Health System, Department of Pharmacy and Drug Information, Atlanta, USA.
⁶ Division of Infectious Diseases, Duke University Health System, Durham VA Health Care System, Durham, NC, USA.

Abstract

[This corrects the article DOI: 10.1155/2019/2989048.].

Publication types

Published Erratum